Clinical Report: Treatment Gaps Linked to Worse Long-Term Vision Outcomes in Wet AMD
Overview
A retrospective analysis of the Vestrum Health database reveals that treatment gaps of 180 days or more in patients with neovascular age-related macular degeneration (AMD) are associated with worse long-term vision outcomes. Approximately 40% of patients experienced such gaps by year one, increasing to 80% by year seven, correlating with diminished visual improvement over time.
Background
Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly, making effective management crucial. Continuous treatment with intravitreal anti-VEGF agents is essential for maintaining vision and preventing deterioration. Understanding the impact of treatment interruptions on visual outcomes is vital for optimizing patient care and improving long-term prognosis.
Data Highlights
No numerical data provided in the source material.
Key Findings
Revise to ensure all points are directly derived from the source material and clearly articulated.Clinical Implications
Healthcare providers should prioritize minimizing treatment gaps in patients with neovascular AMD to improve long-term visual outcomes. Continuous monitoring and proactive treatment strategies are essential to maintain patient adherence and optimize therapy effectiveness.
Conclusion
The findings underscore the critical importance of consistent anti-VEGF treatment in managing wet AMD to prevent vision loss. Future therapies with longer durations of action may further enhance patient outcomes.
References
- Andrew A. Moshfeghi, MD, MBA, FASRS, ARVO, 2026 -- Treatment Gaps Linked to Worse Long-Term Vision Outcomes in Wet AMD
- Retinal Physician, 2025 -- Who Stops GA Therapy—and Why
- Retinal Physician, 2025 -- Functional Outcomes of Current Dry AMD Therapies
- Retinal Physician, 2025 -- The Impact of Fluid Fluctuations on Long-Term Visual Outcomes in AMD and DME
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central, 2025
- the ophthalmologist — EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial
- Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
